CR20200117A - Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use - Google Patents

Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use

Info

Publication number
CR20200117A
CR20200117A CR20200117A CR20200117A CR20200117A CR 20200117 A CR20200117 A CR 20200117A CR 20200117 A CR20200117 A CR 20200117A CR 20200117 A CR20200117 A CR 20200117A CR 20200117 A CR20200117 A CR 20200117A
Authority
CR
Costa Rica
Prior art keywords
angptl3
rnai agents
compositions
angiopoietin
methods
Prior art date
Application number
CR20200117A
Other languages
Spanish (es)
Inventor
Rui Zhu
Zhen Li
So Wong
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Priority claimed from PCT/US2018/050848 external-priority patent/WO2019055633A1/en
Publication of CR20200117A publication Critical patent/CR20200117A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents. Also disclosed are methods of use of ANGPTL3 RNAi agents and compositions. The ANGPTL3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more ANGPTL3 RNAi agents, optionally with one or more additional therapeutics, are described. Deliver}' of the ANGPTL3 RNAi agents in vivo provides for inhibition of ANGPTL3 gene expression, and can result in lower triglycerides and. or cholesterol levels in the subject. The RNAi agents can be used in methods of treatment of ANGPTL3 -related diseases and disorders, including cardiometabolic diseases such as hypertriglyceridemia and hyperlipidemia.
CR20200117A 2017-09-14 2018-09-13 Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use CR20200117A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762558819P 2017-09-14 2017-09-14
US201762583919P 2017-11-09 2017-11-09
US201862651284P 2018-04-02 2018-04-02
PCT/US2018/050848 WO2019055633A1 (en) 2017-09-14 2018-09-13 Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use

Publications (1)

Publication Number Publication Date
CR20200117A true CR20200117A (en) 2020-04-18

Family

ID=70917966

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200117A CR20200117A (en) 2017-09-14 2018-09-13 Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use

Country Status (1)

Country Link
CR (1) CR20200117A (en)

Similar Documents

Publication Publication Date Title
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
ZA202106265B (en) Compositions and methods for inhibiting gene expression of lpa
PH12021550423A1 (en) Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use
ZA202002094B (en) Trispecific proteins and methods of use
MX2021005389A (en) Lipid nanoparticle formulations.
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
IN2015DN00376A (en)
EP4124346A3 (en) Compositions and methods for treating diseases
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
EA201792103A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
EA033448B1 (en) Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
MX2021008261A (en) Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use.
PH12019502660A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
CR20200117A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
EA202090717A1 (en) RNAi MEANS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF ANGIOPOETIN-LIKE PROTEIN 3 (ANGPTL3) AND METHODS OF APPLICATION
EA202090687A1 (en) RNAi AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
WO2016018454A3 (en) Compositions and methods employing bcl2 and bcl2 family members
EA202190800A1 (en) RNA AGENTS FOR INHIBITING EXPRESSION 17beta-HSD TYPE 13 (HSD17B13), THEIR COMPOSITIONS AND METHODS OF APPLICATION